Abstract
It was postulated that N6-allyl bicyclic derivatives 1 bind with N-8 at the proton donor site of the σ1 receptor and that a substituent in 2-position of the bicyclic framework 1 results in unfavorable steric interactions with the σ1 receptor protein. In order to support this hypothesis both enantiomers of 6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[ 3.2.2]non-2-ene (2/ent-2) and 6-benzyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane 3/ent-3 were synthesized stereoselectively. The (S,S)-configured enantiomers 2 and 3 are the eutomers with eudismic ratios of 31 and 4.8, respectively. Therefore, these enantiomers are used in the σ1 pharmacophore model. The N6-allyl derivative 2 with a double bond in the three carbon bridge adopts the orientation 2c with N-8 interacting with the σ1 receptor proton donor site (Fig. 2) resulting in slightly reduced steric interactions of the small double bond in 2/3-position. The almost C2-symmetric benzyl derivative 3 can adopt both orientations 2c and 2d at the σ1 receptor (N-8 or N-6 interacts with the σ 1 receptor proton donor site) resulting in subnanomolar σ1 receptor affinity (Ki = 0.91 nM).
Keywords: ??1 receptor ligands: 6,8-diazabicyclo[3.2.2]nonanes, 6,8-diazabicyclo[3.2.2]nonenes, pharmacophore model
Central Nervous System Agents in Medicinal Chemistry
Title: Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Volume: 9 Issue: 3
Author(s): Ralph Holl, Christian Geiger, Masakazu Nambo, Kenichiro Itami, Dirk Schepmann and Bernhard Wunsch
Affiliation:
Keywords: ??1 receptor ligands: 6,8-diazabicyclo[3.2.2]nonanes, 6,8-diazabicyclo[3.2.2]nonenes, pharmacophore model
Abstract: It was postulated that N6-allyl bicyclic derivatives 1 bind with N-8 at the proton donor site of the σ1 receptor and that a substituent in 2-position of the bicyclic framework 1 results in unfavorable steric interactions with the σ1 receptor protein. In order to support this hypothesis both enantiomers of 6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[ 3.2.2]non-2-ene (2/ent-2) and 6-benzyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane 3/ent-3 were synthesized stereoselectively. The (S,S)-configured enantiomers 2 and 3 are the eutomers with eudismic ratios of 31 and 4.8, respectively. Therefore, these enantiomers are used in the σ1 pharmacophore model. The N6-allyl derivative 2 with a double bond in the three carbon bridge adopts the orientation 2c with N-8 interacting with the σ1 receptor proton donor site (Fig. 2) resulting in slightly reduced steric interactions of the small double bond in 2/3-position. The almost C2-symmetric benzyl derivative 3 can adopt both orientations 2c and 2d at the σ1 receptor (N-8 or N-6 interacts with the σ 1 receptor proton donor site) resulting in subnanomolar σ1 receptor affinity (Ki = 0.91 nM).
Export Options
About this article
Cite this article as:
Holl Ralph, Geiger Christian, Nambo Masakazu, Itami Kenichiro, Schepmann Dirk and Wunsch Bernhard, Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030220
DOI https://dx.doi.org/10.2174/1871524910909030220 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pediatric Chronic Daily Headache
Current Pediatric Reviews Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry The Use of <i>Cannabis</i> and Cannabinoid-based Products by Pregnant Women: A Patent Review
Recent Patents on Biotechnology Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacogenetics of Opioids for the Treatment of Acute Maternal Pain During Pregnancy and Lactation
Current Drug Metabolism Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Molecular Targets of Cannabinoids Associated with Depression
Current Medicinal Chemistry Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites
Current Medicinal Chemistry Synthesis and Structure-Activity Relationship on Anticonvulsant Aryl Semicarbazones
Medicinal Chemistry Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry Editorial [Hot Topic: Organ Involvement in the Antiphospholipid Syndrome (Guest Editors: Gerard Espinosa and Ricard Cervera)]
Current Rheumatology Reviews Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Relevance of Excitable Media Theory and Retinal Spreading Depression Experiments in Preclinical Pharmacological Research
Current Neuropharmacology